Regulatory scientific advice on non-inferiority drug trials.

par Grace Wangge, Michelle Putzeist, Mirjam J Knol, Olaf H Klungel, Christine C Gispen-De Wied, Antonius de Boer, Arno W Hoes, Hubert G Leufkens, Aukje K Mantel-Teeuwisse
Publié 2013

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands

par Christine M. Cramer-van der Welle, Marjon V. Verschueren, Merel Tonn, Bas J. M. Peters, Franz M. N. H. Schramel, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde, The Santeon NSCLC Study Group
Publié 2021

Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes

par Shifteh Abedian, Ali Abbasi, Anthonius de Boer, Bruno H. Stricker, Stephan J. L. Bakker, Pim van der Harst, Sanaz Sedaghat, Maryam Darvishian, M. Arfan Ikram, Gerjan Navis, Abbas Dehghan, Ido Pen, Ronald P. Stolk, Harold Snieder, Olaf H. Klungel, Patrick Souverein, Behrooz Z. Alizadeh
Publié 2021